Parkinson's disease is a neurodegenerative disease which is associated with different
motor, cognitive and mood-related problems. Though it has been established that …

Botulinum neurotoxin type A (BoNT/A) is a metalloprotease that produces a sustained yet
transitory blockade of transmitter release from peripheral nerve terminals. Local delivery of …

Botulinum neurotoxins (BoNTs) are potent inhibitors of synaptic vesicle fusion and
transmitter release. The natural target of BoNTs is the peripheral neuromuscular junction …

Recently, we have designed and synthesized a novel multipotent, brain-permeable iron-
chelating drug, VAR10303 (VAR), possessing both propargyl and monoamine oxidase …

The widely used botulinum neurotoxin A (BoNT/A) blocks neurotransmission via cleavage of
the synaptic protein SNAP‐25 (synaptosomal‐associated protein of 25 kDa). Recent …

Recent animal experiments suggested that centrally transported botulinum toxin type A
(BoNT-A) might reduce an abnormal muscle tone, though with an unknown contribution to …

Parkinson's patients often suffer from depression and anxiety, for which there are no optimal
treatments. Hemiparkinsonian (hemi-PD) rats were used to test whether intrastriatal …

Botulinum neurotoxin (BoNT) inhibits the release of acetylcholine from presynaptic vesicles
through its proteinase activity cleaving the SNARE complex. Parkinson's disease (PD) is …

Botulinum neurotoxins are metalloproteases that specifically cleave N-ethylmaleimide-
sensitive factor attachment protein receptor (SNARE) proteins in synaptic terminals, resulting …

Central pathophysiological pathways of basal ganglia dysfunction imply a disturbed
interaction of dopaminergic and cholinergic circuits. In Parkinson's disease imbalanced …